Plasma ACE2 Activity is an Independent Prognostic Marker in Chagas' Disease and Equally Potent as BNP

Journal of Cardiac Failure

Volumn 16, Issue 2, 2010, Pages 157-163

  Wang, Yong ^a   Moreira, Maria da Consolação V ^b   Heringer Walther, Silvia ^c   Ebermann, Linda ^d   Schultheiss, Heinz Peter ^d   Wessel, Niels ^e   Siems, Wolf Eberhard ^f   Walther, Thomas ^a,g  

^a UNIVERSITY OF HULL   (United Kingdom)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e HUMBOLDT UNIVERSITY   (Germany)

^f LEIBNIZ INSTITUT FÜR MOLEKULARE PHARMAKOLOGIE   (Germany)

^g JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Angiotensin converting enzyme 2; B type natriuretic peptide; Chagas' disease

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; BRAIN NATRIURETIC PEPTIDE;

ADULT; ARTICLE; BLOOD SAMPLING; CHAGAS DISEASE; CONTROLLED STUDY; DISEASE MARKER; DISEASE SEVERITY; ECHOCARDIOGRAPHY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HEART DEATH; HEART FAILURE; HEART GRAFT; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT;

BIOLOGICAL MARKERS; CHAGAS DISEASE; COHORT STUDIES; ENZYME ACTIVATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDYL-DIPEPTIDASE A; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 75349101263     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2009.09.005     Document Type: Article

References (30)

1. Chagas' disease-an epidemic that can no longer be ignored. Lancet 368 (2006) 619
2. Higuchi Mde L., Benvenuti L.A., Martins Reis M., and Metzger M. Pathophysiology of the heart in Chagas' disease: current status and new developments. Cardiovasc Res 60 (2003) 96-107
3. Berger R., Huelsman M., Strecker K., Bojic A., Moser P., Stanek B., et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 105 (2002) 2392-2397
4. Price J.F., Thomas A.K., Grenier M., Eidem B.W., O'Brian Smith E., Denfield S.W., et al. B-type natriuretic peptide predicts adverse cardiovascular events in pediatric outpatients with chronic left ventricular systolic dysfunction. Circulation 114 (2006) 1063-1069
5. Walther T., Heringer-Walther S., Wessel N., Schultheiss H.P., and Moreira Mda C. Brain natriuretic peptide as a predictor of cardiomyopathy in Chagas' disease. Lancet 361 (2003) 1567
6. Heringer-Walther S., Moreira M.C., Wessel N., Saliba J.L., Silvia-Barra J., Pena J.L., et al. Brain natriuretic peptide predicts survival in Chagas' disease more effectively than atrial natriuretic peptide. Heart 91 (2005) 385-387
7. Melo R.B., Parente G.B., and Victor E.G. Measurement of human brain natriuretic peptide in patients with Chagas' disease. Arq Bras Cardiol 84 (2005) 137-140
8. Moreira Mda C., Heringer-Walther S., Wessel N., Moreira Ventura T., Wang Y., Schultheiss H.P., et al. Prognostic value of natriuretic peptides in Chagas' disease: a 3-year follow-up investigation. Cardiology 110 (2008) 217-225
9. Heringer-Walther S., Moreira Mda C., Wessel N., Wang Y., Ventura T.M., Schultheiss H.P., et al. Does the C-type natriuretic peptide have prognostic value in chagas disease and other dilated cardiomyopathies?. J Cardiovasc Pharmacol 48 (2006) 293-298
10. Le T.H., and Coffman T.M. Targeting genes in the renin-angiotensin system. Curr Opin Nephrol Hypertens 17 (2008) 57-63
11. Dzau V.J. Theodore Cooper Lecture: tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 37 (2001) 1047-1052
12. Raizada M.K., and Ferreira A.J. ACE2: a new target for cardiovascular disease therapeutics. J Cardiovasc Pharmacol 50 (2007) 112-119
13. Santos R.A., Simoes e Silva A.C., Maric C., Silva D.M., Machado R.P., de Buhr I., et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A 100 (2003) 8258-8263
14. Harmer D., Gilbert M., Borman R., and Clark K.L. Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme. FEBS Lett 532 (2002) 107-110
15. Gembardt F., Sterner-Kock A., Imboden H., Spalteholz M., Reibitz F., Schultheiss H.P., et al. Organ-specific distribution of ACE2 mRNA and correlating peptidase activity in rodents. Peptides 26 (2005) 1270-1277
16. Epelman S., Tang W.H., Chen S.Y., Van Lente F., Francis G.S., and Sen S. Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system. J Am Coll Cardiol 52 (2008) 750-754
17. Vickers C., Hales P., Kaushik V., Dick L., Gavin J., Tang J., et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 277 (2002) 14838-14843
18. Huang L., Sexton D.J., Skogerson K., Devlin M., Smith R., Sanyal I., et al. Novel peptide inhibitors of angiotensin-converting enzyme 2. J Biol Chem 278 (2003) 15532-15540
19. Hunt S.A., Abraham W.T., Chin M.H., Feldman A.M., Francis G.S., Ganiats T.G., et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 112 (2005) e154-e235
20. Swedberg K., Cleland J., Dargie H., Drexler H., Follath F., Komajda M., et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 26 (2005) 1115-1140
21. Lambert D.W., Yarski M., Warner F.J., Thornhill P., Parkin E.T., Smith A.I., et al. Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J Biol Chem 280 (2005) 30113-30119
22. Boehm M., and Nabel E.G. Angiotensin-converting enzyme 2-a new cardiac regulator. N Engl J Med 347 (2002) 1795-1797
23. Donoghue M., Hsieh F., Baronas E., Godbout K., Gosselin M., Stagliano N., et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 87 (2000) E1-E9
24. Crackower M.A., Sarao R., Oudit G.Y., Yagil C., Kozieradzki I., Scanga S.E., et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 417 (2002) 822-828
25. Gurley S.B., Allred A., Le T.H., Griffiths R., Mao L., Philip N., et al. Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice. J Clin Invest 116 (2006) 2218-2225
26. Yamamoto K., Ohishi M., Katsuya T., Ito N., Ikushima M., Kaibe M., et al. Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II. Hypertension 47 (2006) 718-726
27. Loot A.E., Roks A.J., Henning R.H., Tio R.A., Suurmeijer A.J., Boomsma F., et al. Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation 105 (2002) 1548-1550
28. Mercure C., Yogi A., Callera G.E., Aranha A.B., Bader M., Ferreira A.J., et al. Angiotensin(1-7) blunts hypertensive cardiac remodeling by a direct effect on the heart. Circ Res 103 (2008) 1319-1326
29. Goulter A.B., Goddard M.J., Allen J.C., and Clark K.L. ACE2 gene expression is up-regulated in the human failing heart. BMC Med 2 (2004) 19
30. Greenberg B. An ACE in the hole alternative pathways of the renin angiotensin system and their potential role in cardiac remodeling. J Am Coll Cardiol 52 (2008) 755-757